LNTH recently purchased cancer drugs license which are in the Phase 1 with FDA, that look promising. The company raised some cash through senior convertible notes. Quarterly revenue grew 134% YoY to 239.3mm, driven by strengths across the portfolio. Management raised Q4 and FY22 guidance to the upside from the top-bottom lines. Last ER looks like: Lantheus Non-GAAP EPS of $0.99 beats by $0.16, revenue of 239.29M beats by 11.41M. The stock price retraced to its long term support zone and could start move up towards 80$ area.